Aqualane Clinical Research, a leading organization dedicated in advancing medical therapies, has announced a significant expansion of its facilities to accommodate the growing demand for clinical trials, particularly in the field of neurological disease research. This strategic move, dubbed “Phase 1” of their expansion plan, highlights the increasing importance of clinical research in the healthcare landscape and Aqualane’s commitment to providing patients with access to cutting-edge treatments.
The clinical research field has experienced substantial growth in recent years, driven by the urgent need to develop new and improved therapies for a wide range of medical conditions. Alzheimer’s disease, in particular, has become a focal point for research due to its increasing prevalence and the lack of effective treatments. According to the Alzheimer’s Association, more than 6 million Americans are living with Alzheimer’s, and this number is projected to rise to nearly 13 million by 2050.
Dr. William Justiz, one of Aqualane’s founders, emphasized the significance of this expansion: “Our new facilities, especially our ability to conduct overnight stays for first-in-human trials, represent a major step forward in our research capabilities. This is particularly crucial for research, where closely monitored, round-the-clock observation can provide invaluable data in the early stages of drug development.”
The Phase 1 expansion of Aqualane’s facilities includes the addition of specialized overnight accommodations, state-of-the-art monitoring equipment, and an expanded team of researchers. This enhancement allows Aqualane to conduct first-in-human trials, a critical stage in the drug development process where new treatments are tested in humans for the first time.
Dr. Matthew Baker, another founder of Aqualane, explained the importance of these trials: “First-in-human studies are a pivotal step in bringing new treatments to patients. By offering overnight stays, we can provide continuous monitoring and immediate response to any effects of the new therapies we’re testing. This is especially important in research, where understanding the 24-hour impact of a treatment can be crucial.”
Aqualane continues to conduct trials across a broad spectrum of conditions, including Alzheimer’s, Multiple Sclerosis, Parkinson’s Disease, and various neuropsychiatric disorders. The expansion allows the organization to accommodate an increasing number of clinical trials across all these areas.
Kelly Calistri, also co-founder and CEO, highlighted the patient-centric approach of Aqualane: “Our expanded facilities not only enhance our research capabilities but also allow us to provide a more comfortable and comprehensive experience for our trial participants. We understand that participating in a clinical trial, especially one involving overnight stays, can be daunting. Our new facilities are designed to make patients feel at ease while ensuring the highest standards of care and data collection.”
The growth of Aqualane Clinical Research reflects broader trends in the clinical research field. The global clinical trials market is expected to reach $68.9 billion by 2026, growing at a compound annual rate of 5.1% from 2021 to 2026. This expansion is driven by the increasing prevalence of chronic diseases like Alzheimer’s, the need for personalized medicine, and the growing emphasis on patient-centered care.
Aqualane’s commitment to advancing research is particularly timely. Despite decades of research, effective treatments for various therapies remain elusive, making every new clinical trial a potential breakthrough. The ability to conduct first-in-human trials with overnight stays positions Aqualane at the forefront of this critical research.
“We’re excited about the potential our expanded facilities bring to research,” said Dr. Justiz. “Every day, we’re learning more about these devastating diseases, and each trial brings us one step closer to potential treatments that could improve the lives of millions.”
As Aqualane Clinical Research continues to grow, the organization remains focused on its mission of collaborating with patients, their care partners, and industry sponsors to safely and ethically study emerging therapies. This Phase 1 expansion marks a significant milestone in Aqualane’s journey and reinforces its position as a leader in the clinical research field, dedicated to transforming the future of healthcare.
“Our expanded facilities represent not just growth for Aqualane, but hope for patients and families affected by challenging conditions,” concluded Dr. Baker. “We’re committed to leveraging these new capabilities to accelerate the pace of discovery and bring new treatments to those who need them most.”
With the growing demand for clinical trials, Aqualane’s unwavering dedication to patient-centric research, the future holds immense promise for the advancement of medical therapies and the well-being of patients worldwide.
239-529-6780
3200 Bailey Lane • Suite 250 • Naples, FL 34105
www.aqualaneresearch.com